sulbactam has been researched along with Critical Illness in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 6 (54.55) | 2.80 |
| Authors | Studies |
|---|---|
| Karimzadeh, I; Masjedi, M; Mirjalili, M; Mirzaei, E; Sabetian, G; Vazin, A; Zand, F | 1 |
| Baehner, T; Passon, SG; Schmidt, AR; Velten, M; Wittmann, M | 1 |
| Guo, N; Hu, S; Jiang, J; Leng, B; Shen, C; Zhang, L | 1 |
| Jiang, J; Liu, X; Long, Y; Qiao, L; Wang, Q; Wu, J; Xu, T; Yang, Y; Yu, J; Zhang, B; Zuo, W | 1 |
| Dang, ZL; Li, B; Qin, HY; Rao, Z; Wei, YH; Wu, XA; Zhu, L | 1 |
| Fang, Q; Fang, XL; Hu, J; Lai, YX; Xiao, YH; Zheng, Y | 1 |
| Adnan, S; Lipman, J; Paterson, DL; Roberts, JA | 1 |
| An, R; Du, Z; Gao, C; Sun, Z; Tong, J; Yu, K | 1 |
| Broll, M; Burhenne, H; Burkhardt, O; Clajus, C; Hafer, C; Kaever, V; Kielstein, JT; Knitsch, W; Lorenzen, JM | 1 |
| Acquarolo, A; Candiani, A; Giannotti, C; Latronico, N; Perone, G; Urli, T | 1 |
| Chang, CM; Chuang, YC; Ko, WC; Lee, HC; Lee, NY; Wang, CL; Wang, LR; Yu, WL | 1 |
1 review(s) available for sulbactam and Critical Illness
| Article | Year |
|---|---|
Ampicillin/sulbactam: its potential use in treating infections in critically ill patients.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Ampicillin; Anti-Bacterial Agents; Critical Illness; Drug Resistance, Multiple, Bacterial; Humans; Sulbactam | 2013 |
3 trial(s) available for sulbactam and Critical Illness
| Article | Year |
|---|---|
The clinical and paraclinical effectiveness of four-hour infusion vs. half-hour infusion of high-dose ampicillin-sulbactam in treatment of critically ill patients with sepsis or septic shock: An assessor-blinded randomized clinical trial.
Topics: Ampicillin; Anti-Bacterial Agents; Critical Illness; Humans; Intensive Care Units; Prospective Studies; Sepsis; Shock, Septic; Sulbactam | 2023 |
Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.
Topics: Acinetobacter baumannii; Adult; Aged; Anti-Bacterial Agents; Cefoperazone; Critical Illness; Female; Hemofiltration; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Sulbactam; Young Adult | 2016 |
Antibiotic prophylaxis of early onset pneumonia in critically ill comatose patients. A randomized study.
Topics: Adult; Ampicillin; Antibiotic Prophylaxis; Brain Injuries; Cohort Studies; Coma; Critical Illness; Drug Resistance; Female; Humans; Italy; Male; Middle Aged; Pneumonia; Prospective Studies; Respiration, Artificial; Sulbactam | 2005 |
7 other study(ies) available for sulbactam and Critical Illness
| Article | Year |
|---|---|
Evaluation of continuous ampicillin/sulbactam infusion in critically ill patients.
Topics: Ampicillin; Anti-Bacterial Agents; Critical Illness; Humans; Microbial Sensitivity Tests; Retrospective Studies; Sulbactam | 2023 |
An HPLC-MS/MS method for determination of sulbactam in human plasma and its pharmacokinetic application in critically ill patients with augmented renal clearance.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Critical Illness; Humans; Sulbactam; Tandem Mass Spectrometry | 2023 |
Clinical outcomes and safety of intravenous polymyxin B-based treatment in critically ill patients with carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Critical Illness; Cross Infection; Healthcare-Associated Pneumonia; Humans; Polymyxin B; Retrospective Studies; Sulbactam; Tigecycline | 2023 |
Determination of Total and Unbound Meropenem, Imipenem/Cilastatin, and Cefoperazone/Sulbactam in Human Plasma: Application for Therapeutic Drug Monitoring in Critically Ill Patients.
Topics: Cefoperazone; Chromatography, High Pressure Liquid; Cilastatin; Cilastatin, Imipenem Drug Combination; Critical Illness; Drug Monitoring; Humans; Imipenem; Meropenem; Plasma; Sulbactam; Tandem Mass Spectrometry | 2020 |
Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients.
Topics: Adult; Afibrinogenemia; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Blood Coagulation Tests; Case-Control Studies; Cefoperazone; Critical Illness; Female; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Sulbactam; Tigecycline | 2020 |
Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Anuria; Area Under Curve; Critical Illness; Drug Administration Schedule; Drug Dosage Calculations; Drug Monitoring; Equipment Design; Female; Germany; Half-Life; Humans; Infusions, Intravenous; Male; Membranes, Artificial; Metabolic Clearance Rate; Middle Aged; Models, Biological; Polymers; Prospective Studies; Renal Dialysis; Sulbactam; Sulfones; Young Adult | 2012 |
Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Anti-Bacterial Agents; Bacteremia; Cilastatin; Cilastatin, Imipenem Drug Combination; Critical Illness; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Meropenem; Microbial Sensitivity Tests; Sulbactam; Taiwan; Thienamycins | 2007 |